Empyrean Capital Partners LP acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV – Free Report) during the fourth quarter, HoldingsChannel reports. The fund acquired 104,650 shares of the medical research company’s stock, valued at approximately $23,589,000.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Engineers Gate Manager LP bought a new position in IQVIA in the fourth quarter valued at approximately $5,253,000. First Manhattan CO. LLC. boosted its stake in IQVIA by 5.4% in the fourth quarter. First Manhattan CO. LLC. now owns 268,866 shares of the medical research company’s stock valued at $60,605,000 after acquiring an additional 13,747 shares during the last quarter. Balyasny Asset Management L.P. bought a new position in IQVIA in the fourth quarter valued at approximately $65,244,000. Banco Bilbao Vizcaya Argentaria S.A. boosted its stake in IQVIA by 23.3% in the fourth quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 6,343 shares of the medical research company’s stock valued at $1,432,000 after acquiring an additional 1,200 shares during the last quarter. Finally, Boothbay Fund Management LLC bought a new position in IQVIA in the fourth quarter valued at approximately $3,723,000. 89.62% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently weighed in on the stock. HSBC set a $210.00 price target on shares of IQVIA in a research report on Wednesday, June 3rd. Truist Financial reduced their price target on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research report on Thursday, February 19th. Royal Bank Of Canada assumed coverage on shares of IQVIA in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price target on the stock. TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and lifted their price target for the stock from $174.00 to $213.00 in a research report on Monday, March 9th. Finally, Weiss Ratings cut shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average target price of $222.56.
IQVIA Trading Down 4.8%
Shares of NYSE IQV opened at $170.58 on Thursday. The stock has a market cap of $28.47 billion, a price-to-earnings ratio of 21.14, a P/E/G ratio of 1.54 and a beta of 1.21. IQVIA Holdings Inc. has a twelve month low of $153.01 and a twelve month high of $247.04. The company’s fifty day moving average is $173.77 and its 200-day moving average is $192.26. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20.
IQVIA (NYSE:IQV – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.83 by $0.07. The business had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm’s revenue was up 8.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities research analysts predict that IQVIA Holdings Inc. will post 11.6 EPS for the current year.
IQVIA announced that its board has approved a stock repurchase plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s management believes its stock is undervalued.
About IQVIA
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
Featured Articles
- Five stocks we like better than IQVIA
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
